RxDoctor Payments Data

Nancy Vu, MD

Neurology · Fountain Valley, CANPI 1821059957

Payments from drug & device makers

$21,176in general payments, 2019–2025

Across 673 payments — averaging $31.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Biogen$2K
  • Neurocrine Biosciences, Inc.$1K
  • Novartis$1K
  • EMD Serono, Inc.$1K
  • UCB, Inc.$1K
  • plus $12K from 42 others

What the payments were for

  • Speaking & faculty fees$1221%
  • Food & beverage$20,81098%
  • Education$2441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,176 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$225,462
Medicare patients
589
Services billed
1,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GocovriAmantadine Hcl13$44,353
RexultiBrexpiprazole22$34,364
Nurtec OdtRimegepant Sulfate17$20,779
OngentysOpicapone29$20,571
LinzessLinaclotide19$11,459
UbrelvyUbrogepant11$11,290
Levetiracetam298$10,509
Oxcarbazepine39$6,944
RytaryCarbidopa/Levodopa12$6,822
Divalproex Sodium149$6,587
Carbidopa-LevodopaCarbidopa/Levodopa184$6,447
Memantine Hcl ErMemantine Hcl51$5,064
Diclofenac Sodium86$4,632
Baclofen77$4,363
Lacosamide44$4,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$471$44,35313 claims
Otsuka America Pharmaceutical, Inc.Rexulti$320$34,36422 claims
AbbVieLinzess, Ubrelvy$2,423$22,74830 claims
PfizerNurtec Odt$148$20,77917 claims
Neurocrine Biosciences, Inc.Ongentys$1,486$20,57129 claims
Amneal Pharmaceuticals LLCRytary$247$6,82212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →